Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that David Rabuka, Ph.D, Global Head of Research and Development, Chemical Biology, Catalent Biologics, will be presenting at the upcoming 7th Protein and Antibody Engineering Summit (PEGS Boston), to be held at the Seaport World Trade Center, Boston, Massachusetts, on May 1 – 5, 2017.
On Wednesday, May 3rd Rabuka, is expected to present during the ‘Antibody-Drug Conjugates I: New Targets, Payloads and Alternative Formats’ conference track. His presentation discusses the latest advances in developing antibody-drug conjugates using Catalent’s SMARTag® Technology.
In the presentation, Rabuka will examine the growth of antibody-drug conjugates in clinical trials and pre-clinical development following on from the successes of the approved antibody-drug conjugates drugs brentuximab vedotin (Adcetris™; Seattle Genetics/Takeda) and ado-trastuzumab emtansine (Kadcyla™; Genentech/Roche). He will discuss how innovations in conjugation chemistry and linker technologies suggest further opportunities in the development of antibody-drug conjugates, and review pre-clinical studies using Catalent’s SMARTag technology platform, which enables precise, programmable, site-selective chemical protein modification.
In addition, Anne Marie Rogan, Senior Associate Scientist at Catalent Biologics’ analytical services will be showcasing expert posters on the use of LC-MS to monitor levels of oxidation and deamidation in proteins for release and stability. Finally, Luke Deters, Senior Manager, Large Molecule Analytical Chemistry will present a poster discussing “quantitation and characterization of polysorbate-80 by HPLC and charged aerosol detection.
Catalent’s proprietary SMARTag site-specific protein-modification and linker technologies were originally developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create one or more aldehyde tags at designated sites on protein molecules. These chemical “handles’’ are then stably conjugated to payloads (e.g. cytotoxic or effector) to prevent their systemic release. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation and defined stoichiometry of drug–protein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates.
Catalent acquired Redwood Bioscience in 2014.
Disclosure: David Rabuka, Ph.D, is a member of the editorial advisory board of ADC Review, Journal of Antibody-drug Conjugates.